Skip to main content

Table 1 Outcomes and additional measures

From: Evaluation of a practice team-supported exposure training for patients with panic disorder with or without agoraphobia in primary care - study protocol of a cluster randomised controlled superiority trial

Measure

Description

Timeline

  

Before baseline

T0

T1

T2

Primary outcome

BAI

Clinical severity of anxiety

 

•

•

•

Secondary outcomes

MI (subscale ‘alone’)

Agoraphobic avoidance behaviour

 

•

•

•

PAS (Items A1 and A2)

Number and severity of panic attacks

 

•

•

•

PHQ-9

Depressiveness

 

•

•

•

PACIC (short form)

Patients’ perspectives on receipt of care

 

•

•

•

EQ-5D

Health-related quality of life

 

•

•

•

CSSRI (modified version)

Health service use and productivity losses

 

•

•

•

Additional measures

Screening questionnaire: OASIS; PHQ (panic module)

Patient-reported severity of anxiety symptoms and presence of diagnostic criteria for panic disorder

•

   

Diagnostic interview (ICD-10-based checklist)

GP-reported diagnosis of panic disorder and agoraphobia

•

   

Comorbid physical and mental disorders

GP-reported ICD-10 diagnoses

•

   

Sociodemographic characteristics

Patient-reported age, sex, level of education, and marital status

 

•

  

Treatment adherence questionnaire (self-developed)

Patient-reported adherence to self-managed exposure exercises

  

•

 

GPs’ usual care

GP-reported referrals to psychiatric or psychological treatments (past six months)

  

•

•

  1. Note. T0 = baseline before intervention; T1 = follow-up at six months; T2 = follow-up at twelve months; BAI = Beck Anxiety Inventory; CSSRI = Client Sociodemographic and Service Receipt Inventory; EQ-5D = EuroQol questionnaire; GP = general practitioner; MI = Mobility Inventory; OASIS = Overall Anxiety Severity and Impairment Scale; PACIC = Patient Assessment of Chronic Illness Care questionnaire; PAS = Panic and Agoraphobia Scale; PHQ = Patient Health Questionnaire. The treatment adherence questionnaire is not administered in the control group.